Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Replication‐competent vaccinia virus was used as the vaccine in the campaign to eradicate smallpox. After the disease was eradicated, recombinant vaccinia viruses were created that were capable of expressing foreign genes. This made vaccinia‐based systems available for mammalian cell expression of recombinant protein, an advantage of which, like other mammalian expression systems, is authentic posttranslational modification. Generation of recombinant vaccinia also provided an opportunity for developing vaccinia‐based vaccines for use against nonpoxvirus diseases. In this respect, recombinant vaccinia virus and recombinant versions of an attenuated derivative, Modified Vaccinia virus Ankara (MVA) have been extensively studied. Today, there are recombinant vaccinia viruses expressing foreign antigens in phases I–III clinical trials relating to viral, bacterial, parasitic and cancer‐related diseases, and a licensed veterinary vaccine. Key Concepts: Smallpox was eradicated following a vaccination campaign in which live vaccinia virus was used as the vaccine. Foreign genes can be inserted into the vaccinia virus genome to create recombinant vaccinia virus strains. The vaccinia virus expression system allows for mammalian cell expression of recombinant protein, an advantage of which is authentic post‐translational modification. Recombinant vaccinia can deliver vaccine antigens and evoke potent cell‐mediated and humoral responses specific to the inserted gene. Vaccination with recombinant organisms can confer protection against viral, bacterial, parasitic and cancer‐related diseases.
Replication‐competent vaccinia virus was used as the vaccine in the campaign to eradicate smallpox. After the disease was eradicated, recombinant vaccinia viruses were created that were capable of expressing foreign genes. This made vaccinia‐based systems available for mammalian cell expression of recombinant protein, an advantage of which, like other mammalian expression systems, is authentic posttranslational modification. Generation of recombinant vaccinia also provided an opportunity for developing vaccinia‐based vaccines for use against nonpoxvirus diseases. In this respect, recombinant vaccinia virus and recombinant versions of an attenuated derivative, Modified Vaccinia virus Ankara (MVA) have been extensively studied. Today, there are recombinant vaccinia viruses expressing foreign antigens in phases I–III clinical trials relating to viral, bacterial, parasitic and cancer‐related diseases, and a licensed veterinary vaccine. Key Concepts: Smallpox was eradicated following a vaccination campaign in which live vaccinia virus was used as the vaccine. Foreign genes can be inserted into the vaccinia virus genome to create recombinant vaccinia virus strains. The vaccinia virus expression system allows for mammalian cell expression of recombinant protein, an advantage of which is authentic post‐translational modification. Recombinant vaccinia can deliver vaccine antigens and evoke potent cell‐mediated and humoral responses specific to the inserted gene. Vaccination with recombinant organisms can confer protection against viral, bacterial, parasitic and cancer‐related diseases.
Replication‐competent Vaccinia virus was used as the vaccine in the campaign to eradicate smallpox. After the disease was eradicated, recombinant Vaccinia viruses were created that were capable of expressing foreign genes. This made Vaccinia‐based systems available for mammalian cell expression of recombinant protein, an advantage of which, similar to other mammalian expression systems, is authentic posttranslational modification. Generation of recombinant Vaccinia also provided an opportunity for developing Vaccinia‐based vaccines for use against nonpoxvirus diseases. In this respect, recombinant Vaccinia virus and recombinant versions of an attenuated derivative, Modified Vaccinia virus Ankara (MVA) have been extensively studied. Today, there are recombinant Vaccinia viruses expressing foreign antigens in phases I–III clinical trials relating to viral, bacterial, parasitic and cancer‐related diseases, and a licensed veterinary vaccine. Key Concepts Smallpox was eradicated following a vaccination campaign in which live Vaccinia virus was used as the vaccine. Foreign genes can be inserted into the Vaccinia virus genome to create recombinant Vaccinia virus strains. The Vaccinia virus expression system allows for mammalian cell expression of recombinant protein, an advantage of which is authentic posttranslational modification. Recombinant Vaccinia can deliver vaccine antigens and evoke potent cell‐mediated and humoral responses specific to the inserted gene. Vaccination with recombinant organisms can confer protection against viral, bacterial, parasitic and cancer‐related diseases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.